About the Event
This installment of Psychiatry and Behavioral Sciences Grand Rounds features Wayne K. Goodman, M.D., presenting “Deep Brain Stimulation for Intractable Obsessive-Compulsive Disorder.” Goodman is a professor and chair of the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine.
Email Renee Collins for the Zoom information.
By the end of this event series, the audience participant should be able to:
- Identify which medications have been shown effective for OCD based on randomized clinical trials.
- Apply an evidence-based pharmacologic approach to patients with OCD who have not experienced an adequate response to an SSRI.
- Evaluate whether a patient with OCD would be a possible candidate for Deep Brain Stimulation.
- Primary: Psychiatrists, Social Workers, Psychologists, Nurses and other Mental Health Professionals
- Secondary: Other health care professionals
This activity has been designed to promote some of the following desired physician attributes and competencies:
- ACGME: Patient Care; Medical Knowledge; Practice-Based Learning and Improvement; Interpersonal and Communication Skills; Professionalism; Systems-Based Practice.
- IOM: Provide patient-centered care; Work in interdisciplinary teams; Employ evidenced-based practice; Apply quality improvement; Utilize informatics.
- IECC: Interprofessional Teamwork & Team-based Practice; Interprofessional Communication; Values & Ethics for Interprofessional Practice
Goodman has reported the following relevant relationships with ineligible companies:
- Grants/Research support received from Biohaven Pharmaceuticals
- Consultant for Biohaven Pharmaceuticals.
- Honoraria received from Biohaven Pharmaceuticals.
Goodman has received donated medical devices from Medtronic.
Robert E. Feinstein, M.D.; Roshni Koli, M.D.; Jorge Almeida, M.D., Ph.D.; Lowell McRoberts, M.D.; Cathy Stacy, Ph.D.; Kathryn Flowers; and Renee Collins, planners for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.
Jeff Newport, M.D., planner for this educational activity, reported the following relevant financial relationship(s)with ineligible companies:
- Grants/Research support: Eli Lilly, Glaxo SmithKline (GSK), Janssen, National Alliance for Research on Schizophrenia and Depression (NARSAD), National Institutes of Health (NIH), Sage Therapeutics, Takeda Pharmaceuticals, Texas Health & Human Services Commission, Wyeth.
- Honorarium: Astra-Zeneca, Eli Lilly, GSK, Pfizer, Wyeth.
- Speaker’s Bureau: Astra-Zeneca, Eli Lilly, GSK, Pfizer, Wyeth.
- Other (please describe):
- Advisory Boards: GSK, Janssen, Sage Therapeutics.
Steve Strakowski, M.D., planner for this educational activity, reported the following relevant financial relationship(s) with ineligible companies:
- Grants/Research support: Janssen.
- Consultant: Sunovion (Data & Safety Monitoring Board Chair), Otsuka (Data Monitoring Committee member).
- Honorarium: Medscape.
Charles Nemeroff, M.D., Ph.D., planner for this educational activity, reported the following relevant financial relationship(s) with ineligible companies:
- National Institutes of Health (NIH).
- Consulting: ANeuroTech (division of Anima BV), Taisho Pharmaceutical, Inc., Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage, BioXcel Therapeutics, Silo Pharma, Aditum Bio, XW Pharma
- Stockholder: Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness
- Board of Directors: Gratitude America, ADAA, Xhale Smart, Inc.
- Income sources or equity of $10,000 or more: American Psychiatric Publishing, Xhale, Signant Health, CME Outfitters, Takeda, Intra-Cellular Therapies, Inc., EMA Wellness
- Patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2)
- Scientific Advisory Boards: ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety Disorders Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS
All of the relevant financial relationships listed for these individuals have been mitigated.
The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas at Austin Dell Medical School designates this internet live course for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.